Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Second malignancies in multiple myeloma; emerging patterns and future directions

Maclachlan, Kylee ; Diamond, Benjamin ; Maura, Francesco ; Hillengass, Jens ; Turesson, Ingemar LU ; Landgren, C. Ola and Kazandjian, Dickran (2020) In Best Practice and Research: Clinical Haematology 33(1).
Abstract

The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and... (More)

The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Autologous, Lenalidomide, Melphalan, Multiple myeloma, Neoplasms, Risk factors, Second primary, Transplantation
in
Best Practice and Research: Clinical Haematology
volume
33
issue
1
article number
101144
publisher
Elsevier
external identifiers
  • scopus:85078481537
  • pmid:32139010
ISSN
1521-6926
DOI
10.1016/j.beha.2020.101144
language
English
LU publication?
yes
id
5928a87a-a070-4db4-bcc3-1fc6e85d3602
date added to LUP
2020-02-06 14:19:43
date last changed
2024-06-27 12:27:48
@article{5928a87a-a070-4db4-bcc3-1fc6e85d3602,
  abstract     = {{<p>The changing landscape of treatment options for multiple myeloma has led to a higher proportion of patients achieving deep, long-lasting responses to therapy. With the associated improvement in overall survival, the development of subsequent second malignancies has become of increased significance. The risk of second malignancy after multiple myeloma is affected by a combination of patient-, disease- and therapy-related risk factors. This review discusses recent data refining our knowledge of these contributing factors, including current treatment modalities which increase risk (i.e. high-dose melphalan with autologous stem cell transplant and lenalidomide maintenance therapy). We highlight emerging data towards individualized risk- and response-adapted treatment strategies and discuss key areas requiring future research.</p>}},
  author       = {{Maclachlan, Kylee and Diamond, Benjamin and Maura, Francesco and Hillengass, Jens and Turesson, Ingemar and Landgren, C. Ola and Kazandjian, Dickran}},
  issn         = {{1521-6926}},
  keywords     = {{Autologous; Lenalidomide; Melphalan; Multiple myeloma; Neoplasms; Risk factors; Second primary; Transplantation}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Elsevier}},
  series       = {{Best Practice and Research: Clinical Haematology}},
  title        = {{Second malignancies in multiple myeloma; emerging patterns and future directions}},
  url          = {{http://dx.doi.org/10.1016/j.beha.2020.101144}},
  doi          = {{10.1016/j.beha.2020.101144}},
  volume       = {{33}},
  year         = {{2020}},
}